NCT07238062

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs for the Treatment of Multiple System Atrophy."

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Hope Biosciences Research Foundation · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: —

Summary

This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass pre-screening and a completed screening. The subjects will receive 12 intravenous infusions of HB-adMSCs and 6 intrathecal injections of HB-adMSCs over the course of 44 weeks (1 infusion each month and 1 injection every other month).

Conditions

• Multiple System Atrophy

Interventions

Type	Name	Description
BIOLOGICAL	HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells	Intravenous and intrathecal infusion of Hope Biosciences allogeneic adipose-derived stem cells

Timeline

• First posted: 2025-11-20
• Last updated: 2026-04-17

Locations

1 site across 1 country: United States